In the context of MMRd CRC tumors, we observed complete responses of 25%, 12%, 59% and 71% for anti-PD-1/TIM3, anti-PD-1/TIGIT, anti-PD-1/LAG3 and anti-PD1/LAG3/CTLA4 respectively (Figure 4 D, Extended Figure 15 D). This evidence concerns the gene TIGIT and colorectal carcinoma.